Biosimilar medicine authorized by the AEMPS
ACTIVE PRINCIPLE: Omalizumab
DATE: 06/09/2024
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.
PRIVACY POLICY
SUBSCRIBE
